ArticleNature communications2026
Bioresorbable electrochemical sensors for continuous deep-tissue lactate monitoring in critical care.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Lactate is a key metabolite and prognostic biomarker, reflecting oxygen delivery, cellular demand, and mitochondrial function. Current clinical lactate monitoring, however, relies on intermittent blood sampling, limiting localized interrogation, dynamic tracking and early intervention in critical care. Here, we report a bioresorbable and flexible electrochemical sensor for continuous deep-tissue lactate monitoring. By leveraging a previously unreported enzyme-assisted proton-intercalation mechanism, we establish a unique electrochemical sensing interface that enables high-performance lactate detection entirely with biodegradable materials. Integrated with a wireless module, the device enables in vivo real-time recording with excellent sensitivity and stable operation over clinically relevant timescales (> 10 days), without requiring secondary surgeries for device retrieval. The sensor robustly captures organ-specific lactate dynamics during hypoxia and epileptic seizures. Notably, we identify that increases in pericardial lactate precede systemic changes detected by conventional monitoring in septic shock, providing a prominent marker for early warning and timely intervention. Pericardial lactate-guided treatment markedly improves hemodynamic stability and prevents septic shock within the monitoring window. This work enables paradigm-shifting strategies for bioresorbable, implantable sensors that monitor vital metabolites in real time, supporting early diagnosis, guided intervention and improved outcomes in intensive care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.